Mortality and morbidity in transsexual subjects treated with cross‐sex hormones

@article{Kesteren1997MortalityAM,
  title={Mortality and morbidity in transsexual subjects treated with cross‐sex hormones},
  author={P. V. van Kesteren and H. Asscheman and J. Megens and L. Gooren},
  journal={Clinical Endocrinology},
  year={1997},
  volume={47}
}
  • P. V. van Kesteren, H. Asscheman, +1 author L. Gooren
  • Published 1997
  • Medicine
  • Clinical Endocrinology
  • The optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. We have investigated the mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment. 
    391 Citations
    Long-term cross-sex hormone treatment is safe in transsexual subjects.
    • 14
    • PDF
    Hormone management of trans men
    • 1
    Hormone Treatment of the Adult Transsexual Patient
    • L. Gooren
    • Medicine
    • Hormone Research in Paediatrics
    • 2005
    • 95

    References

    SHOWING 1-10 OF 32 REFERENCES
    Mortality and morbidity in transsexual patients with cross-gender hormone treatment.
    • 155
    • PDF
    Ischemic cerebrovascular disease and hormone therapy for infertility and transsexualism
    • 11
    Physical and hormonal evaluation of transsexual patients: A longitudinal study
    • 116
    An androgen‐associated hepatic adenoma in a trans‐sexual
    • 24
    Sex reassignment surgery: A study of 141 dutch transsexuals
    • 130
    Exogenous estrogen effect on lipid /lipoprotein cholesterol in transsexual males
    • 25
    PROLACTIN LEVELS AND PITUITARY ENLARGEMENT IN HORMONE‐TREATED MALE‐TO‐FEMALE TRANSSEXUALS
    • 84
    Cerebrovascular occlusion in a transsexual man taking mestranol.
    • 20